Video

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Shilpa Gupta, MD, oncologist, Hematology and Medical Oncology, Cleveland Clinic, discusses the addition of cabozantinib (Cabometyx) to avelumab (Bavencio) in locally advanced or metastatic urothelial cancer.

The phase 3 MAIN-CAV trial (NCT05092958) is evaluating the combination of cabozantinib plus avelumab vs avelumab alone in patients with metastatic urothelial cancer.

Maintenance avelumab is currently the standard of care for patients with metastatic urothelial cancer who have not progressed following first-line treatment with platinum-based chemotherapy, Gupta says. The MAIN-CAV trial is investigating the intensification of maintenance avelumab with the VEGF inhibitor, cabozantinib, to evaluate if the combination can improve overall survival, Gupta explains.

Various subgroups within urothelial cancer do not derive as high of a benefit from maintenance avelumab alone, Gupta continues. This prompted the investigation of maintenance with cabozantinib plus avelumab, Gupta adds. The trial is currently active and accruing patients, Gupta concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center